| アブストラクト | BACKGROUND: Hepatic cancer is a common cancer in clinical practice. Current drug therapies for this condition include targeted therapy, chemotherapy, and immunotherapy. Tumor lysis syndrome (TLS) is the most serious complication of oncology treatment. According to the literature, several cases reported TLS occurred with targeted therapies for hepatic cancer. METHODS: Reporting odds ratio and information component were used to measure the disproportionate signals for TLS associated with targeted therapies, using data from the FDA's Adverse Event Reporting System (FAERS). A stepwise sensitivity analysis was conducted to test the robustness of signals. Time-to-onset analysis was used to describe the latency of TLS events associated with targeted therapies. The Bradford Hill criteria were used to perform a global assessment of the evidence. RESULTS: Sorafenib, lenvatinib, cabozantinib, and bevacizumab showed higher disproportionate signals for TLS than chemotherapy. The median number of days to TLS occurrence after drug therapy was 5.5, 6.5, and 6.5 days for sorafenib, lenvatinib, and bevacizumab, respectively. CONCLUSIONS: There is a significant association between tumor lysis syndrome and targeted therapies for hepatic carcinoma, with particularly strong signals for sorafenib and lenvatinib. Clinicians should be aware of the potential for tumor lysis syndrome in targeted therapies for hepatic carcinoma. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| 投稿日 | 2024/1/30 |
|---|
| 投稿者 | Liu, Ling; Zhang, Chengyi; Liu, Huihui; Luo, Huan; Cao, Rong; Xiao, Mingxuan; Zou, Pan; Xie, Zhuzhu; Gong, Hui; Ma, Rui; Yan, Miao; Jiang, Zhichao |
|---|
| 組織名 | Hunan University of Chinese Medicine, Changsha, China.;Department of Pharmacy, The Second Xiangya Hospital, Central South University,;Changsha, China.;Guangdong Provincial People's Hospital Zhuhai Hospital (Zhuhai Golden Bay Center;Hospital), Zhuhai, China.;The First Affiliated Hospital of Hunan Traditional Chinese Medical College,;Zhuzhou, China.;China Pharmaceutical University, Nanjing, China.;Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.;International Research Center for Precision Medicine, Transformative Technology;and Software Services, Changsha, China.;Toxicology Counseling Center of Hunan Province (TCCH), Changsha, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38288971/ |
|---|
